Dear BioPharmCatalyst reader, I am pleased to announce that the chatroom has had a complete revamp for the benefit of all users of BioPharmCatalyst. The previous chatroom was admittedly poorly designed and as a result received little attention. It was not user-friendly and in fact most readers were unaware it existed. However, as of today [...]
Earlier today abstracts to next month’s ASCO meeting were released. Approximately 75 of those abstracts can now be found in the BioPharmCatalyst ASCO Calendar, which can be found HERE. Session times and other information can also be found to give you a one-stop resource provided to save you much time in searching for abstracts.
The following is a list of some companies with upcoming meetings (May – June 2012) where shareholders will be asked to vote to give permission to enforce a reverse split and/or change (usually increase) the number of authorised shares. REVERSE SPLIT VOTES: BIONOVO INC (BNVI): May 3 – Reverse Split vote at a ratio of 1-for-250. [...]
Initial Public Offering listing on Nasdaq Global Select Market under the symbol “SUPN” likely week of Apr 30-May 4, 2012. Pipeline: SEVERAL upcoming catalysts SPN-538 (extended release topiramate) for epilepsy. NDA filed with PDUFA date in July 2012. Topiramate is marketed by Johnson & Johnson under the brand name Topamax and is available in a generic form. Topiramate [...]
I am pleased to announce that the ASCO 2012 Calendar has been added to BioPharmCatalyst. You can find it next to the FDA Calendar tab. Abstract numbers, presentation types and times, drugs and indications are all available in the calendar. Links to abstracts will be added as soon as they are uploaded onto the ASCO website on [...]
The Financial Database has been updated to include cash positions as of the end of 2011 for approximately 175 small and mid cap biotech companies. This is the second quarter where cash positions have been inputted, allowing readers to compare cash positions of various companies from the previous quarter. In order to get a much more [...]
See individual posts made in the last week for more detail. PDUFA/NDA FILINGS/ADVISORY COMMITTEE NEWS Delcath Systems, Inc. (Nasdaq: DCTH) intends to refile its NDA during 2Q 2012 for the treatment of patients with metastatic melanoma in the liver. Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) - PDUFA date of June 27 set for lorcaserin in patients with obesity. AVEO Pharmaceuticals, Inc. (NASDAQ: [...]
As many of you may be aware BMY offered INHX $26 per share for its acquisition last week. I posted on twitter a link detailing a SEC filing noting that it had offered $20/share just the previous week only to be informed that it needed to increase its bid as another company was offering more. I have pasted [...]
Readers now have the opportunity to view recent S-3 shelf filings in the Financial Database. Such a filing is required to comply with SEC regulations before filing a public offering. S-3 filings remain valid for up to three years. A shelf offering is not an immediate offering of shares. Rather, it gives the company an option to sell [...]
See individual posts made in the last week for more detail. PDUFA/NDA FILINGS/ADVISORY COMMITTEE NEWS AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) said that it intends to file its NDA for tivozanib during 2012 following full data release at ASCO this year. Cornerstone Therapeutics (NASDAQ: CRTX) – NDA for lixivaptan for the treatment of hyponatremia was filed on Dec. 29, [...]
A Merry Xmas to all readers of BioPharmCatalyst. Thank you all for your support over the past year and wish you all a relaxing break with friends and family! See individual posts made in the last week for more detail. PDUFA/FDA RELATED EVENTS Santarus, Inc. (NASDAQ: SNTS) submitted its NDA for UCERIS for mild to [...]
Dear BioPharmCatalyst reader, I am pleased to announce that the chatroom has had a complete revamp for the benefit of all users of BioPharmCatalyst. The previous chatroom was admittedly poorly designed and as a result received little attention. It was not user-friendly and in fact most readers were unaware it existed. However, as of today [...]
Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced the initiation of a Phase 2 trial of ZEVALIN for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL). Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced efficacy and safety results from its Phase 2 trial of urocortin 2 in 53 patients [...]
Earlier today abstracts to next month’s ASCO meeting were released. Approximately 75 of those abstracts can now be found in the BioPharmCatalyst ASCO Calendar, which can be found HERE. Session times and other information can also be found to give you a one-stop resource provided to save you much time in searching for abstracts.
Recent Comments